Head to head
NMN against MIB-626
Consumer NMN against the pharmaceutical grade NMN that was actually put through randomised trials. MIB-626 raised blood NAD substantially in all three placebo-controlled trials and changed muscle strength, aerobic capacity, insulin sensitivity and liver fat in none of them.
Column A
NMNNicotinamide Mononucleotide
A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a contested regulatory status in the US.
Column B
MIB-626MIB-626, a microcrystalline polymorph of beta-nicotinamide mononucleotide
The only NMN product with a real randomised trial programme: three placebo-controlled trials totalling about 104 participants, all of which measured blood NAD and safety. It raised blood NAD substantially every time. It did not change muscle strength, aerobic capacity, insulin sensitivity, liver fat, or any marker of kidney injury or inflammation in hospitalised patients.
Side by side, on the facts we can check
| Attribute | NMN | MIB-626 |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Not an approved drug; US supplement status contested | An investigational drug in the United States, developed under an IND by Metro International Biotech. It is not approved for any indication and is not the same regulatory object as NMN sold as a dietary supplement, although the molecule is identical. The existence of that IND is what triggered FDA's 2022 determination excluding NMN from the dietary supplement definition, a determination FDA reversed in September 2025. |
| Half-life | Short | The pharmacokinetic trial measured blood NMN and NAD exposure rather than a clean elimination half-life. NMN itself clears quickly and very little unmodified NMN was recovered in urine, while the downstream NAD rise built gradually over days and peaked late in the dosing period. |
| Molecular weight | 334.2 Da | 334.2 Da. It is beta-nicotinamide mononucleotide; the proprietary part is the crystal form, not the molecule. |
| Mechanism | Converts to NAD+ through the salvage pathway, aiming to restore NAD+ levels that decline with age. | The active molecule is beta-nicotinamide mononucleotide, which enters NAD synthesis one step below nicotinamide riboside: NMN is adenylylated by NMNAT enzymes directly to NAD, bypassing the NAMPT step that limits nicotinamide. The proprietary element is formulation rather than pharmacology, a defined microcrystalline polymorph intended to give reproducible, pharmaceutical-grade exposure, which is what allows dose-ranging and regulatory filing in a way a variable supplement powder does not. A 2026 human study raised the alternative possibility that orally administered NMN and NR raise systemic NAD partly through gut microbial conversion to nicotinic acid, which if confirmed would apply to this product as much as to any other oral NMN. |
| Human studies cited | 2 | 4 |
| Legal status, US | Not approved; FDA excluded it from the supplement definition (2022) | Investigational, not approved |
Frequently asked questions
What is the difference between NMN and MIB-626?
NMN: A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a contested regulatory status in the US. MIB-626: The only NMN product with a real randomised trial programme: three placebo-controlled trials totalling about 104 participants, all of which measured blood NAD and safety. It raised blood NAD substantially every time. It did not change muscle strength, aerobic capacity, insulin sensitivity, liver fat, or any marker of kidney injury or inflammation in hospitalised patients.
Which has stronger research evidence, NMN or MIB-626?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the NMN profile were human work, against 4 of 4 for MIB-626. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are NMN and MIB-626 FDA-approved?
NMN: Not an approved drug; US supplement status contested. MIB-626: An investigational drug in the United States, developed under an IND by Metro International Biotech. It is not approved for any indication and is not the same regulatory object as NMN sold as a dietary supplement, although the molecule is identical. The existence of that IND is what triggered FDA's 2022 determination excluding NMN from the dietary supplement definition, a determination FDA reversed in September 2025..
Related posts
Blog articles that cover NMN or MIB-626, newest first.
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Metabolic / Sep 8, 2026 / 7 minSLU-PP-332 and 5-Amino-1MQ: Two 'Peptides' That Are Not Peptides, and What the Mouse Data Actually Show
- Longevity / Sep 8, 2026 / 8 minNMN vs NR vs NAD+: The 2026 Head-to-Head Human Trials, and Who Funded the Comparisons
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.